ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...
Yahoo Finance2 天
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the ...
Business Insider3 天
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of ...
TMCnet4 天
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
(Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited ...
manilatimes3 天
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
(Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited ...
Yahoo Finance3 天
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...